RevolutionEHR announces launch of revMarket

Article

RevolutionEHR announced the launch of revMarket, a cloud-based resource designed for optometrists, during a press conference at SECO on Thursday.

 

 

Atlanta, GA-RevolutionEHR announced the launch of revMarket, a cloud-based resource designed for optometrists, during a press conference at SECO on Thursday.

RevMarket will offer mobile apps, e-prescribing, electronic claims processing, and patient communications, among other services through secure web-service connections.

In related news, the company announced it has added 4 optometrists to its team of advisors. Kelly Kerksick, OD, will serve as a senior adviser on eyecare professional relations. Jason Miller, OD, MBA, will serve as an adviser on practice success. Brett Paepke, OD, will serve as an adviser on Stage 1 Meaningful Use support. Optometry Times Editorial Advisory Board member Mike Rothschild, OD, will serve as an adviser on early stage success. 

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.